Clinical trialPhase 1Withdrawn
Pilot Study of 89-Zr Panitumumab in Pancreas Cancer
Pilot Study of 89Zr Panitumumab in Pancreas Cancer
- Outcome
- Stopped earlyBusiness Decision (Business decision)
- Phase
- Phase 1
- Status
- Withdrawn
- Study type
- Interventional
- Planned start
- 26 March 2021
- Planned end
- March 2024
- Enrollment
- 0 participants
- Sites
- 1
- Primary outcomes
- Incidence of treatment emergent adverse events assessed by CTCAE v5
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 21 June 2024
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular imaging agent in patients with (metastatic) pancreas cancer.